|
 
 |
| ORIGINAL ARTICLE |
|
| Year : 2014 | Volume
: 34
| Issue : 2 | Page : 72-76 |
|
Topoisomerase I inhibitor suppress tumor growth in chemoresistant ovarian cancer-initiating cells
Yu-Chi Wang1, Cheng-Chang Chang1, Kai-Jo Chiang2, Tai-Kuang Chao3, Chia-Chun Wu4, Ping-Ying Chang5, Chang-Chieh Wu6, Hung-Cheng Lai7
1 Department of Obstetrics and Gynecology, Tri-Service General Hospital; Laboratory of Epigenetics and Cancer Stem Cells, National Defense Medical Center, Taipei, Taiwan, Republic of China
2 Department of Nursing, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan, Republic of China
3 Department of Pathology, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan, Republic of China
4 Department of Orthopedic, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan, Republic of China
5 Department of Internal Medicine, Division of Hematology and Oncology, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan, Republic of China
6 Department of Surgery, Division of Colorectal Surgery, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan, Republic of China
7 Department of Obstetrics and Gynecology, Tri-Service General Hospital; Laboratory of Epigenetics and Cancer Stem Cells, National Defense Medical Center; Department of Obstetrics and Gynecology, Taipei Medical University-Shuang Ho Hospital, Zhonghe District, New Taipei City, Taiwan, Republic of China
| Date of Submission | 05-Nov-2013 |
| Date of Decision | 26-Nov-2013 |
| Date of Acceptance | 04-Dec-2013 |
| Date of Web Publication | 5-May-2014 |
Correspondence Address:
Prof. Hung-Cheng Lai
Department of Obstetrics and Gynecology, Taipei Medical University-Shuang Ho Hospital, No. 291, Zhongzheng Road, Zhonghe District, New Taipei City 235, Taiwan
Republic of China
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/1011-4564.131897
Background: To investigate the role of a topoisomerase I inhibitor (topotecan) in chemoresistant ovarian cancer-initiating cells. Materials and Methods: We isolated ovarian cancer-initiating cells (CP70 side-population cells) from the CP70 cell line using FACS Aria-based sorting and cultured them in suspension to form spheroids (CP70 side-population sphere [SPS]). Gene expression was assessed by microarray, to identify potentially effective chemotherapeutic drugs. An MTS assay was used to evaluate cell growth. Results: CP70 SPS cells showed significant resistance to the chemotherapeutic drugs cisplatin and paclitaxel. Microarray analysis demonstrated a high expression of topoisomerase-related genes in CP70 SPS cells. Topotecan inhibited ovarian cancer-initiating cells (CP70 SPS) in vitro more than it did their parental CP70 cells. This result was confirmed in tissues from human patients. Conclusions: Chemoresistant ovarian cancer-initiating cells exhibited high expression levels of topoisomerase, which could be an alternative target of adjuvant therapy for patients with chemoresistant ovarian cancer. Keywords: Chemoresistance, ovarian cancer-initiating cells, topoisomerase I inhibitor, topotecan
How to cite this article:
Wang YC, Chang CC, Chiang KJ, Chao TK, Wu CC, Chang PY, Wu CC, Lai HC. Topoisomerase I inhibitor suppress tumor growth in chemoresistant ovarian cancer-initiating cells. J Med Sci 2014;34:72-6 |
How to cite this URL:
Wang YC, Chang CC, Chiang KJ, Chao TK, Wu CC, Chang PY, Wu CC, Lai HC. Topoisomerase I inhibitor suppress tumor growth in chemoresistant ovarian cancer-initiating cells. J Med Sci [serial online] 2014 [cited 2023 Sep 25];34:72-6. Available from: https://www.jmedscindmc.com/text.asp?2014/34/2/72/131897 |
| Introduction | |  |
Ovarian cancer is the main cause of cancer-associated mortality in gynecological malignancies. The combination of cytoreductive surgery and chemotherapy using paclitaxel and carboplatin is the principal treatment of epithelial ovarian cancer (EOC). [1] Although, the overall and complete response rates in advanced disease are 80% and 40-60%, respectively, most patients eventually relapse after first-line treatment with paclitaxel and carboplatin, with a median progression-free survival of 18 months. [2]
It is currently considered that repopulation of cancer stem cells (CSCs) causes the recurrence of cancer. [3] CSCs are a subset of tumor cells that can self-renew and cause tumor initiation and relapse. [4],[5],[6] These cells are resistant to many treatments, including chemotherapy and radiotherapy. [7] Accordingly, these therapies fail because they just kill differentiated tumors, without eliminating CSCs, which survive and generate new tumors subsequently.
Patients with platinum refractory and resistant tumors are strong candidates for novel investigational approaches and studies of drug resistance. Single-agent therapy is a standard treatment in these patients. Weekly topotecan is a well-tolerated and effective regimen for platinum-resistant ovarian cancer, with considerably less hematological toxicity compared with historical data for the 5 days regimen. The response rate to topotecan therapy for platinum-resistant ovarian cancer is 20-25%. [8],[9] The reason for the responsiveness of platinum-resistant ovarian cancer to topotecan remains unknown. This study was performed to elucidate the role of a topoisomerase I inhibitor (topotecan) in the treatment of chemoresistant ovarian cancer-initiating cells.
| Materials and Methods | | |
Cell lines
We obtained the human ovarian cancer cell line CP70 from Dr Tim Huang's laboratory (Ohio State University, Columbus, OH, USA). Cells were maintained at 37°C (5% CO 2 /air atmosphere) in RPMI-1640 medium (Gibco, Rockville, MD, USA) containing 10% heat-inactivated fetal bovine serum.
Measurement of cytotoxicity
The cells were plated at 5 × 10 3 cells per well in 96-well plates 1 day before drug treatment, and then cotreated with topotecan for 24 h. After washing, we incubated the cells with fresh medium for 72 h, followed by staining with the Cell Titer 96 Aqueous One Solution Reagent (Promega), which contains a novel tetrazolium compound (3- [4,5-dimethylthiazol-2-yl]-5-[3-carboxymethoxyphenyl]-2-[4-sulfophenyl]-2H-tetrazolium, inner salt; MTS) and an electron-coupling reagent (phenazine ethosulfate).
To measure the amount of soluble formazan produced by the cellular reduction of MTS, absorbance was recorded at 490 nM using a 96-well plate reader. We assayed each reaction at least three times. The results were expressed as the ratio of cytotoxicity to the concentration of topotecan, as a percentage of 1- MTS reduction in treated samples compared with untreated samples for the drug alone.
Side-population and sphere-formation analysis
CP70 side-population spheres (SPS) cells were isolated from the CP70 cell line according to our previous study. [10] Briefly, a side population (SP) derived from ovarian cancer cells was obtained using flow cytometry and Hoechst 33342 staining. Cells were cultured in suspension condition (100,000 cells/mL) and allowed to recover at 37°C for 1 h before treatment with the Hoechst dye. Hoechst 33342 (Sigma) was added at a final concentration of 2.5 μg/mL and the cells were incubated at 37°C for 1 h. The ABCG2 inhibitor, GF120918, was added at a final concentration of 50 μg/mL, to confirm the gating area on flow cytometry. Side-population cells exhibited low staining with Hoechst 33342. After sorting, they were plated immediately in ultralow attachment plates (Corning) at a density of 20,000 viable cells/mL in a serum-free mammary epithelial growth medium (MEGM, BioWhittaker) supplemented with B27 (Invitrogen), 20 ng/mL epidermal growth factor (EGF), 20 ng/mL basic fibroblast growth factor (bFGF) (BD Biosciences), and 4 μg/mL heparin (Sigma) until the formation of spheres (SPSs).
Clinical specimen
Following informed consent, tumor samples were obtained from patients undergoing surgical treatment at Tri-Service General Hospital in accordance with the appropriate Institutional Review Boards. Within 1 h after surgical removal, tumors were washed and enzymatically dissociated into single cells. Red blood cells were removed by differential centrifugation. Tumor cells were cultured in either NBE media consisting of neurobasal media (Invitrogen), N2 and B27 supplements (0.53 each; Invitrogen), human recombinant bFGF and EGF (50 ng/ml each; R and D systems), or serum media consisting of Dulbecco's modified eagle medium media (Invitrogen) with 10% fetal bovine serum (Cellgro). For ovasphere culture, uncoated plastic dishes were used. For adherent culture of ovasphere, the plates were precoated with a poly-L-lysine/laminin mixture (Invitrogen).
Statistical analysis
The mean and the standard error of the mean are reported. Data were compared using two-tailed Student's t-tests. Significance was set at P < 0.05.
| Results | | |
CP70 side-population spheres cells were resistant to chemotherapeutic drugs
A SP of the CP70 ovarian cancer cell line was isolated using Hoechst 33342 dye exclusion by flow cytometry. [10] The SP was cultured in serum-free medium in a low attachment culture dish until the formation of spheres, which were termed CP70 SPSs [Figure 1]. In our data, CP70 SPS cells showed significant resistance to the chemotherapeutic drugs cisplatin and paclitaxel (P < 0.05), which are used commonly in clinical practice to treat patients with ovarian cancer [Figure 2]. This suggests that CP70 SPS populations are more resistant to chemotherapeutic drugs compared with the parental CP70 cells. | Figure 1. CP70 cells were cultured in suspension condition to form a spheroid tumor, termed CP70 side-population spheres
Click here to view |
 | Figure 2: CP70 side-population spheres cells were resistant to chemotherapeutic drugs of cisplatin and paclitaxel (*P < 0.05)
Click here to view |
Microarray analysis of CP70 side-population spheres compared with CP70 cells
To identify potential chemotherapeutic drugs for chemoresistant ovarian cancer-initiating cells, a microarray analysis was performed to evaluate the expression profile of CP70 SPS cells. Topoisomerase-related genes were highly expressed, as demonstrated in a heat map [Figure 3]. Furthermore, we used RT-PCR to evaluate the expression level of messenger ribonucleic acids (RNAs), which revealed that topoisomerase-related genes (TOP1MT, TOP1P2, and TOPORS) were overexpressed in CP70 SPS compared with CP70 cells [Figure 4]. These data indicate that topoisomerase-related genes are highly expressed in tumor-initiating cells. | Figure 3: Heat maps illustrating the high expression of topoisomerase-related genes in chemoresistant ovarian cancer-initiating cells. Each colored element corresponds to one gene. Higher expression is shown in deep red; lower expression is shown in light red
Click here to view |
 | Figure 4: Relative messenger ribonucleic acid expression level (normalized to GAPDH) of topoisomerase-related genes in CP70 side-population spheres and CP70 cells. TOP1MT, topoisomerase (deoxyribonucleic acid [DNA]) I, mitochondrial; TOP1P2, topoisomerase (DNA) I pseudogene 2; TOPORS, topoisomerase I binding, arginine/serine-rich
Click here to view |
Topotecan inhibited the growth of chemotherapy-resistant ovarian cancer-initiating cells
Next, we examined the effects of topotecan treatment on CP70 and CP70 SPS cells. Cells were cultured in the presence of increasing concentrations of topotecan for 3 days. After incubation, cell viability was measured with the MTS assay. Topotecan exerted a more pronounced growth inhibition (by 13.5 and 12%, respectively) on CP70 SPS than it did on CP70 (by 3.29 and 0.02%, respectively) cells at a concentration of 0.02 and 0.01 μM (P < 0.05) [Figure 5]. In addition, we incubated CP70 SPS cells in adherent conditions for differentiation. Topotecan had an inhibitory effect on cell growth in the cells with stem status compared with those in the differentiated condition (P < 0.05) [Figure 6]. These results demonstrated that topotecan had a selective inhibitory effect on SPS, suggesting that topotecan has a more pronounced effect on cancer-initiating cells. | Figure 5: Effect of topotecan on cancer cell death in CP70 and CP70 sidepopulation spheres cells (*P < 0.05)
Click here to view |
 | Figure 6: Tumor-suppressive effect of topotecan in CP70 side-population spheres cells differentiated to CP70 cells (*P < 0.05)
Click here to view |
Next, we investigated the effect of topotecan on tumor cells derived from human patients with ovarian cancer. Similar to what was observed in the in vitro study, topotecan at different concentrations had a greater inhibitory effect on SPS cells than differentiated cells isolated from the tissue of patients with ovarian cancer [Figure 7]. These results demonstrated that topotecan inhibited SPS cells derived from tumors from patients with ovarian cancer. | Figure 7: Inhibitory effects of topotecan on side-population spheres cells derived from tumors of human patients with ovarian cancer
Click here to view |
| Discussion | | |
The origin and pathogenesis of EOC have long been studied but remain poorly understood. The relapse of ovarian cancer in most patients is likely the result of the sparing of ovarian CSCs. The analysis of tumor samples from patients who had undergone first-line chemotherapy showed an enrichment of stem cell markers, such as CD133, CD44, and ALDH1, compared with samples obtained during surgical cytoreduction. [11] Another study showed that ovarian CSCs located close to the stroma form a possible stem cell niche. [12] To date, no definitive markers of ovarian CSCs have been identified; hence, testing for susceptibility to various chemotherapeutic agents has been inconclusive. The high expression levels of CSC markers were enhanced in a population of cells that responded to cisplatin and paclitaxel treatment. [13] We also identified a subset of ovarian cancer-initiating cells that exhibited an enhanced ability to form spheres in response to chemotherapy drugs. [10] Increased resistance to paclitaxel and cisplatin is associated with ovarian CSCs. [14] Various therapeutic interventions can eliminate CSCs. [15]
The importance of telomerase in tumorigenesis is fully recognized. [16] Telomerase activity and dysfunctional telomeres have been demonstrated in human ovarian carcinoma. [17] Telomerase is not present in the normal ovarian surface epithelium and premalignant lesions, but is upregulated in 90-97% of ovarian carcinomas. [18] To the best of our knowledge, no report has elucidated the role of deoxyribonucleic acid (DNA) topoisomerase I inhibitors in cancer-initiating cells. In our study, a microarray analysis demonstrated elevated expression of topoisomerase-related genes in chemoresistant ovarian cancer-initiating cells. Our results of in vitro and human-tissue studies confirmed that topotecan inhibits the growth of CP70 SPS cells. This study demonstrated that topoisomerase I inhibitors may have a tumor-suppressive effect in ovarian cancer-initiating cells.
A previous report demonstrated that the RET finger protein (RFP) confers resistance to chemotherapeutic drugs in cancer cells. RFP was highly expressed in patients with ovarian cancer and correlated with chemotherapeutic resistance. The use of RNA interference to deplete RFP in ovarian cancer cell lines promoted carboplatin - or paclitaxel-induced apoptosis and decreased chemotherapeutic resistance. [19] Perturbed DNA topoisomerase I activity can affect fragile-site breakage at the RET oncogene. [20] The topoisomerase I inhibitor topotecan may stabilize the fragile-site breakage of the RET oncogene and render cancer cells more sensitive to chemotherapy.
| Conclusion | | |
We demonstrated that topoisomerase-related genes are highly expressed in chemoresistant ovarian cancer-initiating cells. A topoisomerase I inhibitor (topotecan) had a tumor-suppressive effect in chemoresistant ovarian cancer-initiating cells. The use of topotecan in the treatment of cancer-initiating cells could be an adjuvant therapy for the treatment of patients with chemoresistant ovarian cancer.
| Acknowledgments | | |
- This study was supported by grants from National Science Council, Taiwan, Republic of China (ROC); grant number: NSC102-2314-B-016-043; Tri-Service General Hospital, Taiwan, Republic of China (ROC); grant numbers: TSGH-C102-008-S01; TSGH-C102-008-S02; TSGH-C102-008-S03.
- The authors thank Yu-Ping Liao and Tien-Shuo Huang at Laboratory of Epigenetics and CSCs, National Defense Medical Center, Taipei, Taiwan for assistance of statistical and figures management.
| Disclosure | | |
The authors declared this study has no conflicts in interest.
| References | | |
| 1. | Kim A, Ueda Y, Naka T, Enomoto T. Therapeutic strategies in epithelial ovarian cancer. J Exp Clin Cancer Res 2012;31:14. 
|
| 2. | Rubin SC, Randall TC, Armstrong KA, Chi DS, Hoskins WJ. Ten-year follow-up of ovarian cancer patients after second-look laparotomy with negative findings. Obstet Gynecol 1999;93:21-4.
|
| 3. | Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: Accumulating evidence and unresolved questions. Nat Rev Cancer 2008;8:755-68.
|
| 4. | Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997;3:730-7.
|
| 5. | Clarke MF, Fuller M. Stem cells and cancer: Two faces of eve. Cell 2006;124:1111-5.
|
| 6. | Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001;414:105-11.
|
| 7. | Hambardzumyan D, Squatrito M, Holland EC. Radiation resistance and stem-like cells in brain tumors. Cancer Cell 2006;10:454-6.
|
| 8. | Abushahin F, Singh DK, Lurain JR, Grendys EC, Rademaker AW, Schink JC. Weekly topotecan for recurrent platinum resistant ovarian cancer. Gynecol Oncol 2008;108:53-7.
|
| 9. | McGonigle KF, Muntz HG, Vuky J, Paley PJ, Veljovich DS, Greer BE, et al. Combined weekly topotecan and biweekly bevacizumab in women with platinum-resistant ovarian, peritoneal, or fallopian tube cancer: Results of a phase 2 study. Cancer 2011;117:3731-40.
|
| 10. | Yo YT, Lin YW, Wang YC, Balch C, Huang RL, Chan MW, et al. Growth inhibition of ovarian tumor-initiating cells by niclosamide. Mol Cancer Ther 2012;11:1703-12.
|
| 11. | Steg AD, Bevis KS, Katre AA, Ziebarth A, Dobbin ZC, Alvarez RD, et al. Stem cell pathways contribute to clinical chemoresistance in ovarian cancer. Clin Cancer Res 2012;18:869-81.
|
| 12. | Steffensen KD, Alvero AB, Yang Y, Waldstrøm M, Hui P, Holmberg JC, et al. Prevalence of epithelial ovarian cancer stem cells correlates with recurrence in early-stage ovarian cancer. J Oncol 2011;2011:620523.
|
| 13. | Abubaker K, Latifi A, Luwor R, Nazaretian S, Zhu H, Quinn MA, et al. Short-term single treatment of chemotherapy results in the enrichment of ovarian cancer stem cell-like cells leading to an increased tumor burden. Mol Cancer 2013;12:24.
|
| 14. | Zhang S, Balch C, Chan MW, Lai HC, Matei D, Schilder JM, et al. Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res 2008;68:4311-20.
|
| 15. | Guddati AK. Ovarian cancer stem cells: Elusive targets for chemotherapy. Med Oncol 2012;29:3400-8.
[PUBMED] |
| 16. | Shay JW, Wright WE. Senescence and immortalization: Role of telomeres and telomerase. Carcinogenesis 2005;26:867-74.
|
| 17. | Baykal A, Thompson JA, Xu XC, Hahn WC, Deavers MT, Malpica A, et al. In situ human telomerase reverse transcriptase expression pattern in normal and neoplastic ovarian tissues. Oncol Rep 2004;11:297-302.
|
| 18. | Shay JW, Wright WE. Hallmarks of telomeres in ageing research. J Pathol 2007;211:114-23.
|
| 19. | Horio M, Kato T, Mii S, Enomoto A, Asai M, Asai N, et al. Expression of RET finger protein predicts chemoresistance in epithelial ovarian cancer. Cancer Med 2012;1:218-29.
|
| 20. | Dillon LW, Pierce LC, Lehman CE, Nikiforov YE, Wang YH. DNA topoisomerases participate in fragility of the oncogene RET. PLoS One 2013;8:e75741.
|
[Figure 1], [Figure 2], [Figure 3], [Figure 4], [Figure 5], [Figure 6], [Figure 7]
| This article has been cited by | | 1 |
Molecular mechanisms of drug resistance in ovarian cancer |
|
| Leyla Norouzi-Barough,Mohammad Reza Sarookhani,Mohammadreza Sharifi,Sahar Moghbelinejad,Saranaz Jangjoo,Rasoul Salehi | | Journal of Cellular Physiology. 2018; | | [Pubmed] | [DOI] | | | 2 |
A multicenter, open-label, expanded phase 2 study to evaluate the safety and efficacy of etirinotecan pegol, a polymer conjugate of irinotecan, in women with recurrent platinum-resistant or refractory ovarian cancer |
|
| G. Rustin,I. Vergote,J.P. Micha,L.R. Duska,N. Reed,J. Bendell,D. Spitz,G. Dark,U. Hoch,M. Tagliaferri,A.L. Hannah,A.A. Garcia | | Gynecologic Oncology. 2017; | | [Pubmed] | [DOI] | |
|
 |
|
|
|
Search Pubmed for